Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Eli Lilly (NYSE: LLY) Files For Next-Gen Weight-Loss Drug Retatrutide In Q1 2027, Leaving Novo Nordisk (NYSE: NVO) Scrambling

Eli Lilly (NYSE: LLY) has officially confirmed it will submit a Biologics License Application to the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. The announcement marks a major milestone for the drugmaker, which already leads the weight-loss market through its blockbuster medication Zepbound. The filing timeline puts Eli Lilly in an increasingly dominant position over its closest rival, Novo Nordisk (NYSE: NVO)…